CPRX News 2.06 Catalyst Pharmaceutical Partners (CPRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Catalyst Pharmaceutical Partners (CPRX) 2.06 $CPRX

Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89.

Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome

A Small-Cap Biotech Stock on the Verge of a Breakout
at The Street - Wed Apr 09, 1:58PM CDT
This small-cap biotech stock should be on your trading radar.

Catalyst Pharmaceutical Partners concludes public offering at USD2.21 per share
M2 - Wed Apr 09, 5:08AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) revealed on Tuesday the completion of its public offering at an offering price of USD2.21 per share.

Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
GlobeNewswire - Tue Apr 08, 9:30AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 13,023,750 shares of its common stock in the offering, including 1,698,750 shares that were issued upon the exercise by the underwriters of their overallotment option. The offering price was $2.21 per share, and the net proceeds from the sale of the shares is expected to be $26.8 million. Piper Jaffray & Co. acted as the sole book-running manager for the offering, Roth Capital Partners acted as co-lead manager, and H.C. Wainwright & Co., LLC acted as co-manager with respect to the offering.

Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. was a big mover last session, as its shares rose nearly 9% on the day.

3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Catalyst Pharmaceutical Partners prices public offering at USD2.21 per share
M2 - Fri Apr 04, 6:13AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday that it has priced its public offering of 11,325,000 shares of its common stock at USD2.21 per share.

Pandora Media March Active Listener Hours Up 14% in March; eBay Looking to Grow Annual Revenue to $21B by 2015
ACCESSWIRE - Thu Apr 03, 11:20PM CDT
Pandora Media, Inc. (NYSE: P) - For an in-depth report on Pandora Media, Inc. follow: www.BullTrends.com/stockquote/P

Catalyst Pharmaceutical Partners, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 8:00AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any.

Catalyst Pharmaceutical Partners to begin public offering of common shares
M2 - Thu Apr 03, 5:07AM CDT
Specialist pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) said on Wednesday that it plans to offer shares of its common stock in a public offering.

Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Wed Apr 02, 3:04PM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it intends to offer shares of its common stock in a public offering. Catalyst also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Catalyst plans to use the net proceeds from the offering (i) for the continuing development of Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS, (ii) for pre-commercialization activities relating to Firdapse(TM), (iii) for the continuing development of CPP-115, and (iv) for general corporate purposes.

Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.

Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).

Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
GlobeNewswire - Fri Mar 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, FDA-approved medicines targeting orphan neuromuscular and neurological diseases, today announced the appointment of Barrett S. McGrath as Chief Commercial Officer, a newly created position. McGrath will lead the formation of Catalyst's North America commercial strategy and organization. McGrath will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst.

Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.

Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse(TM)
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.

Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:

Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.

Narrower-than-Expected Loss at Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:20AM CDT
Catalyst Pharma incurred a loss of 5 cents in the fourth quarter.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Customers Bancorp, Inc. Faces Class Action Lawsuit

Updated Category News Views 179

Introduction to the Class Action Lawsuit Against Customers Bancorp Recently, Customers Bancorp, Inc. found itself at the center of a significant legal challenge. A securities class action lawsuit has been initiated in federal court on behalf of investors who purchased or acquired shares of Customers Bancorp, Inc. (NYSE: CUBI) during a specific time frame. This action...

Continue Reading
Projected Growth in the Aluminum Beverage Can Industry

Updated Category News Views 238

Exploring the Future of the Aluminum Beverage Can Market As the aluminum beverage can industry steers toward a monumental future, it's evident that the market has grown significantly, evolving to meet the rising demand for sustainable and practical packaging solutions. With a valuation of US$ 36.95 billion in 2024, projections indicate a remarkable increase to US$ 61.12...

Continue Reading
Cybersecurity Initiative Launches for Global Nonprofit Protection

Updated Category News Views 87

Global Leaders Unite for Nonprofit Cybersecurity Influential figures from various sectors gathered at the historic Peace Palace to advocate for better cybersecurity within the nonprofit sector. This initiative, known as 'BEYOND125, Securing Our World's Digital Future,' is focused on tackling significant cybersecurity challenges faced by millions of organizations around...

Continue Reading
Guarda Wallet's Gas-Free USDT Revolution on Tron

Updated Category News Views 44

The Frictionless Future of USDT on the Tron Network You know, it seems like every few months we hear about some innovation that's going to 'revolutionize' crypto transactions. But here's something that's actually shifting the gears—a practical workaround for a typical problem faced by the average Joe trading in stablecoins. Welcome to Guarda Wallet's gas-free...

Continue Reading
Ultragenyx and Mereo BioPharma Stocks Face Significant Decline

Updated Category News Views 130

Overview of Current Situation Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) saw their stock values significantly drop recently, causing concern among investors. The decline comes in light of new developments from their ongoing clinical trials for a drug targeting a rare genetic disorder. What Unfolded? The duo announced updates...

Continue Reading